|
|
||||||||
1 Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA
2 Center for Biodefense and Emerging Infections and Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555, USA
3 University of Texas M. D. Anderson Cancer Center, Bastrop, TX 78602, USA
Correspondence
Ashok K. Chopra
achopra{at}utmb.edu
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Although outbreaks of pneumonic plague are rare, cases were reported in Manchuria in the early 20th century, and later in Madagascar (Inglesby et al., 2000
). Y. pestis, a category A select agent, is easily cultivated, and causes rapid damage in humans when introduced via the aerosolized route (Inglesby et al., 2000
). Furthermore, intentional release of the bacteria would most likely occur by this route (Inglesby et al., 2000
). In fact, Y. pestis was used as a biological weapon against China during World War II, and it has been a focus of subsequent bioweapon development programmes in the USA and the former Soviet Union (Inglesby et al., 2000
).
Some information regarding pneumonic disease presentation in mice, and the response of the host to infection following intranasal administration of the bacterium, has been reported (Bubeck et al., 2007
; Lathem et al., 2005
, 2007
; Sha et al., 2008
). Intranasal entry facilitates channelling of the bacteria into the bloodstream, bypassing the lymphatics, resulting in a rapid dissemination of bacteria to the other organs of the body. Additionally, a biphasic response (an anti-inflammatory phase followed by a proinflammatory phase) has been noted after intranasal administration of Y. pestis CO92 to mice, and this was indicative of a delay in the response of the host to infection (Lathem et al., 2005
). Although difficult to test, as strains of Y. pestis that are negative for type III secretion system do not establish serious infections in vivo, it is presumed that the early anti-inflammatory response (24–36 h p.i.) is induced by the type III secretion system and its associated effectors, while the later proinflammatory response (36–72 h p.i.) results from from the production of various cytokines and chemokines [e.g. interleukin (IL)-6, macrophage chemoattractant protein (MCP)-1, etc.]. In our most recent study, we observed a time-associated progression of plague bacterial dissemination ranging between 72 and 96 h following an intranasal inoculation of mice, as well as rises in cytokine and chemokine levels, and an increase in the severity of tissue injury (Sha et al., 2008
). At a 5 LD50 dose of Y. pestis CO92, the majority of the mice succumbed to infection and died when infected by the intranasal route (Sha et al., 2008
). Smith et al. reported the development of pneumonic plague in mice via the aerosolization of Y. pestis (Smith et al., 1957
), and, since then, several studies have utilized an aerosol model to test the efficacies of plague vaccine combinations (Anderson et al., 1996
; Andrews et al., 1996
; Glynn et al., 2005
; Heath et al., 1998
; Hill et al., 2006
; Jones et al., 2006
; Williamson et al., 2007
). However, currently there are no reports detailing the kinetics of pneumonic plague development and host immune response by aerosolization of virulent Y. pestis CO92 in mice. Therefore, the present study was designed to examine the disease progression, cytokine release and tissue injury that resulted from the aerosolization of virulent Y. pestis CO92 in a mouse model.
| METHODS |
|---|
|
|
|---|
Aerosol challenge of mice.
Our study was conducted under an animal protocol approved by the University of Texas Medical Branch Institutional Animal Care and Use Committee. Mice were exposed to Y. pestis CO92 aerosols in a whole-body Madison chamber (Madison), which was attached in tandem to a class III biological glove cabinet (Baker Company IsoGARD 14), and then to a class II biological safety cabinet, as previously described (Peterson et al., 2007
). Aerosolization of the pathogen was conducted in the aerobiology suite within the restricted access Animal Biosafety Level 3 laboratory. Female 5- to 6-week-old Swiss-Webster mice were purchased from Charles River Laboratories. Various concentrations of Y. pestis CO92 were aerosolized using a three-jet Collison nebulizer, and mice were exposed to the pathogen for 15 min while the aerosol chamber was flushed with air at a flow rate of 50 l min–1, as described recently for Bacillus anthracis spores (Peterson et al., 2007
).
Histopathology.
At 1, 24, 48 and 72 h p.i., lung, liver, spleen and heart tissues from Y. pestis-infected mice (five mice per time point) were collected in screw-cap containers at necropsy, and immersion-fixed in 10 % neutral, buffered formalin. The tissues remained in this solution for 3 days, after which they were placed in new vials with fresh formalin, examined for sterility, routinely processed, sectioned at 5 µm, mounted on glass slides, and stained with haematoxylin and eosin. Bacteria were easily seen in infected tissues using this stain, but we also used Giemsa stain to visualize bacteria in tissues when needed (Sha et al., 2008
). Light microscopic evaluation of the tissues was then performed. The lesions resulting from Y. pestis infection have been previously described (Sha et al., 2008
), and they were graded based on a severity scale correlating with estimates of lesion distribution and type, ranging from minimal to severe (minimal, 2–10 %; mild, 10–20 %; moderate, 20–50 %; severe, >50 %). Briefly, acute inflammation indicated the presence of neutrophils, while subacute inflammation suggested a mixture of neutrophils and mononuclear cells. Oedema and necrosis were observed in tissues having both acute and subacute inflammation accompanied by either moderate or severe lesions. We analysed tissues from five animals per group, and presented the data from representative tissues.
Bacterial dissemination.
Mice were exposed to a 6 LD50 dose of aerosolized Y. pestis CO92. Beginning at 1 h p.i., and continuing at 24, 48 and 72 h p.i., groups of five mice were killed using a mixture of ketamine (90 mg kg–1) and xylazine (10 mg kg–1), and the lungs, liver, spleen and heart were removed immediately after death had been ensured by cervical dislocation. We drew blood from the heart before cervical dislocation of the animals. The organs were weighed, and homogenized in 1 ml sterile water containing 25 µg ml–1 polymyxin B (to facilitate specific growth of Y. pestis CO92) using tissue grinders (Kendall). The blood and tissue homogenates were serially diluted in sterile water with polymyxin B, and cultured on SBA. Plates were incubated at 28 °C for 48 h, after which bacterial colonies were counted, and c.f.u. per gram of tissue or per millilitre of blood was calculated.
In vivo cytokine analysis.
Mice were exposed to a 6 LD50 dose of aerosolized Y. pestis CO92. Beginning at 1 h p.i., and continuing at 24, 48 and 72 h p.i., groups of five mice were killed; organs were harvested at every time point, and blood was collected via cardiac puncture from the 1 and 72 h p.i. groups for cytokine analysis. Sera were filtered once through a 0.45 µm syringe filter, and then once through a 0.22 µm syringe filter, before they were cultured on SBA to confirm that bacteria had been successfully removed from the samples prior to analysis. The levels of 23 different cytokines and chemokines were measured using the multiplex assay with Bio-Plex (Bio-Rad), as previously described (Sha et al., 2008
).
Statistical analyses.
Kaplan–Meier survival estimates of 10 mice per group were used for comparison of the LD50 survival curves. Whenever appropriate, Student's t-test, or ANOVA with Bonferroni post-test, was utilized for statistical analysis between groups. The LD50 determination experiments were repeated twice with 10 mice per dose of the bacteria. For studies on bacterial dissemination and cytokine profiling, we used 15 mice: five were used for collection of tissues and blood, while 10 were observed for mortality. The latter experiment was repeated twice.
| RESULTS AND DISCUSSION |
|---|
|
|
|---|
|
Interestingly, the LD50 dose we previously calculated for intranasal administration of Y. pestis to the same species of mice was 340 c.f.u. (Sha et al., 2008
). These differences in the calculated LD50 doses between two pneumonic models (intranasal versus aerosol) might be due to the mode and efficiency of bacterial entry into the lungs. Alternatively, the lower LD50 dose of Y. pestis CO92 via the intranasal versus the aerosol route might be due to nebulization during aerosolization, as this could affect virulence determinant(s) (e.g. pili, toxins, etc.) present on the bacterial surface; this would thereby increase the number of bacteria necessary to cause infection via the aerosolized route.
Histopathology following aerosolization
To assess tissue injury occurring following aerosol-administered Y. pestis (Dp 1.3x104 c.f.u. ml–1) in mice, we killed five animals at 1, 24, 48 and 72 h p.i., and harvested and formalin-fixed the lungs, liver, spleen and heart. For brevity, histopathology is shown for control animals (1 h p.i.) and animals at 72 h p.i. in Fig. 2
. The animal tissues harvested 1 h p.i. served as appropriate negative controls, as we noted in our previous aerosol studies (data not shown) that animals 1 h post-diluent (no bacteria) exposure showed neither pathology nor alterations in cytokine and chemokine levels compared with uninfected mice that had not been subjected to aerosolization of the diluent.
|
At 48 h p.i., four of the five mice had lung inflammation associated with blood vessels, as observed in the 24 h p.i. mice. Four of the mice had mild acute inflammation and liver necrosis, with occasional bacteria observed in one of the animals. The spleens of three of the mice exhibited neutrophilic infiltrates and some necrotic cells in the red pulp (data not shown). There were no significant lesions present in the hearts of any mice at 48 h p.i.
At 72 h p.i., the mice infected with the highest presented dose of bacteria (1.3x104 c.f.u. ml–1) began to die, and this was reflected in the histopathology of their tissues. The lungs of all mice were inflamed (Fig. 2E, I
, inflammatory cells indicated by arrowheads) as in the 24 and 48 h p.i. groups, but the reaction was more prominent with oedema (asterisks), and the presence of small-to-large groups of bacteria (arrows); these characteristics are common in pneumonic plague infections (Inglesby et al., 2000
). All mice had acute inflammatory changes in the liver, with necrosis (Fig. 2F, J
, asterisks), the presence of fibrin, and a variable number of rod-shaped bacteria (arrows). All five mice had moderate lymphoid depletion in the white pulp of the spleen, and variable numbers of bacteria (Fig. 2G, K
, arrows), with congestion, oedema (at asterisks), and fibrin and cellular loss in the red pulp. The spleen was also infiltrated with inflammatory cells (arrowheads). The heart showed occasional intravascular bacteria (Fig. 2H, L
, arrows). Using Giemsa staining, we also noted the presence of Y. pestis (based on size and morphology) in different organs of infected mice.
We noticed a relatively rapid onset of infection, resulting in the death of the animals within 72–96 h p.i. after exposure to aerosolized Y. pestis CO92. This is in agreement with other studies that have indicated that the slightest delay in antibiotic (doxycycline, ciprofloxacin or chloramphenicol) treatment results in death from pneumonic plague (Gradon, 2002
; Inglesby et al., 2000
). Our own studies also indicated that if the antibiotic treatment (e.g. levofloxacin) was delayed in mice by 36–48 h after infection with Y. pestis CO92 via the intranasal route, animals succumbed to infection (data not shown). The histopathology reported herein in this aerosol model was quite similar to that that we (Sha et al., 2008
) and others (Bubeck et al., 2007
; Lathem et al., 2005
) reported, having used the intranasal model, i.e. immediate effects were seen in mouse lungs by 24 h p.i., as well as liver and spleen involvement beginning 48 h p.i. In contrast, an earlier study that utilized an aerosol model reported no remarkable changes in the livers of infected mice for up to 72 h p.i. (Smith, 1959
). These differences between the studies may be due to variations in bacterial strain or dose, mouse strain, or aerosolization conditions (e.g. airflow through the aerosol chamber) (Glynn et al., 2005
).
Bacterial dissemination following aerosolization over a 72 h period
At 1, 24, 48 and 72 h p.i. with Y. pestis CO92, mice were anaesthetized, and blood was drawn via cardiac puncture, after which the animals were killed, and the organs were harvested, homogenized, and cultured on SBA, as described in Methods. As expected, a general upward trend in the number of bacteria was found in different organs, and this was indicative of a successful bacterial infection. Bacteria multiplied in the lungs in the first 24 h p.i., having increased in number by 1–2 logs, but the most substantial increase was by 3 logs between 48 and 72 h p.i. (Fig. 3A
). An increase in the number of bacteria (by approx. 5 logs) reported at 72 h p.i. was not considered a statistically significantly increase compared with bacterial numbers 1–24 h p.i.; this was because of a single mouse in which only a marginal increase in bacterial number was noted when compared with the other four mice at 72 h p.i. Similar changes in bacterial numbers over the course of infection have been seen in an earlier aerosol study (Smith et al., 1957
), and in other reports in which mice were infected via the intranasal route (Bubeck et al., 2007
; Lathem et al., 2005
). In contrast, in our most recent study using the intranasal route, we observed an initial drop in the number of bacteria in the lungs of mice at 24 h p.i., but noted rises similar to those described above in the numbers of bacteria up to 72 h p.i. (Sha et al., 2008
).
|
In vivo cytokine analysis
The organ homogenates and blood from infected mice at 1 and 72 h p.i. were analysed for cytokine profiles using Bio-Plex, as described in Methods. We chose to compare the levels of cytokines and chemokines in control animals (1 h p.i.) with the levels in mice at 72 h p.i., based on our previous study in which we detected most changes in cytokine and chemokine levels in the sera at the later time point of 96 h p.i. (Sha et al., 2008
). The sera and tissues from animals 1 h p.i. had similar levels of cytokines and chemokines as noted in the sera and tissues of uninfected (subjected to aerosolization with the diluent alone) control mice. For the 23 cytokines and chemokines in the Bio-Plex mouse panel, differences in levels at the two time points were noted in 17 tissue homogenates, as displayed in Fig. 4
. For the remaining six cytokines and chemokines in the panel, we noticed either no detectable level at both 1 and 72 h p.i., or the levels were unusually high in the control animals, and so these results were left out of our analysis. There were statistically significant increases in the concentrations of 13 of the cytokines and chemokines detected in the lung homogenates at 72 h p.i. when these samples were compared with the 1 h control sample, while the remaining four [macrophage inflammatory protein (MIP)-1
, RANTES (regulated upon activation, normal T cell-expressed and -secreted), IL-9, and MIP-1β] showed an increasing trend (Fig. 4A
). Cytokines and chemokines that exhibited 100- to 1000-fold or greater increases from 1 h to 72 h p.i. are denoted with the symbol
(Fig. 4B
). Specifically of interest were the dramatic increases in proinflammatory cytokines, such as IL-1β, IL-1
, interferon (IFN)-
, IL-12(p70), tumour necrosis factor (TNF)-
, and IL-6 at 72 h p.i. compared with their levels in the control; previous studies utilizing an intranasal model have shown similar increases in various cytokines and chemokines (Bubeck et al., 2007
; Lathem et al., 2005
; Sha et al., 2008
). Of additional interest were the substantial increases seen in the levels of granulocyte macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF), which function in the proliferation and survival of monocytes and neutrophils, respectively, as well as in the levels of the chemoattractants MCP-1 (monocytes) and KC, which is the human equivalent of IL-8 (neutrophils).
|
, IFN-
, IL-12(p70), G-CSF and the chemoattractants MCP-1 and KC (100- to 1000-fold or greater, denoted with the symbol
, Fig. 4D
) in the levels of IL-1
, IL-6, G-CSF, KC and MCP-1 at 72 h p.i. All other cytokine and chemokine levels detected in the heart showed an increasing trend from 1 to 72 h p.i.
The spleen homogenates (Fig. 4G, H
) and blood samples (Fig. 4I, J
) of the five mice at each time point were pooled, preventing us from statistically analysing these data; however, the figures represent typical results from two independent experiments. We had to pool these samples because of the thickness of the blood and tissue homogenates; the thickness was the result of the development of overwhelming infection, and it made it difficult to filter out small samples from each mouse. We noted an upward trend of cytokine and chemokine levels following infection with Y. pestis CO92; the results were similar to those seen in the lungs, liver and heart of mice at 72 h p.i., and indicated a severe systemic proinflammatory response late in infection. These data were in agreement with our recent studies documenting the effect of Y. pestis infection when the bacteria were introduced into mice via the intranasal route, as there was an increase in the production of various cytokines and chemokines in the sera (Sha et al., 2008
). Specifically of interest in the spleen were the substantial increases (denoted with the symbol
, and represented by fold increase in Fig. 4H, J
) in the levels of MCP-1, KC, G-CSF, IL-1
and IFN-
, while the blood showed dramatic increases in the levels of the MIP-1β, MIP-1
, MCP, IL-1β, IL-1
, IFN-
, IL-12(p70), IL-6, KC and G-CSF at 72 h p.i. These data indicated that within 72 h after infection, powerful and systemic recruitment of inflammatory cells, and release of proinflammatory cytokines, were initiated as a result of infection with aerosolized Y. pestis.
Conclusions
The virulent bacterium Y. pestis CO92 causes a severe infection and illness (pneumonia) in humans and animals when given by the inhalation routes. Thus, the present study provided a comprehensive examination of infection kinetics of Y. pestis when administered to mice by the aerosol route using a whole-body Madison chamber. Tissue damage was evident at 24 h p.i. in the lungs, as assessed by histopathology, and between 48 and 72 h p.i. in peripheral tissues, as demonstrated by both histopathological and proinflammatory cytokine analyses. Bacteria increased in numbers within 24 h p.i. in the lungs, and between 24 and 72 h p.i. they disseminated rapidly to the peripheral tissues. These data indicated the similarity of the model to the more commonly used intranasal model, and that both inhalational models are appropriate for the study of pneumonic plague. However, to mimic bacterial infection following an intentional release of virulent Y. pestis in the environment as a result of bioterrorism, the aerosol model of plague is more suitable for studying progression of the disease. In this report, we have fully characterized the mouse model in terms of bacterial dissemination, histopathology and cytokine profiling after aerosolization of Y. pestis CO92.
| ACKNOWLEDGEMENTS |
|---|
Edited by: P. van der Ley
| REFERENCES |
|---|
|
|
|---|
Andrews, G. P., Heath, D. G., Anderson, G. W., Jr, Welkos, S. L. & Friedlander, A. M. (1996). Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 64, 2180–2187.[Abstract]
Bubeck, S. S., Cantwell, A. M. & Dube, P. H. (2007). Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice. Infect Immun 75, 697–705.
Cathelyn, J. S., Crosby, S. D., Lathem, W. W., Goldman, W. E. & Miller, V. L. (2006). RovA, a global regulator of Yersinia pestis, specifically required for bubonic plague. Proc Natl Acad Sci U S A 103, 13514–13519.
Doll, J. M., Zeitz, P. S., Ettestad, P., Bucholtz, A. L., Davis, T. & Gage, K. (1994). Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona. Am J Trop Med Hyg 51, 109–114.
Glynn, A., Roy, C. J., Powell, B. S., Adamovicz, J. J., Freytag, L. C. & Clements, J. D. (2005). Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens. Infect Immun 73, 5256–5261.
Gradon, J. D. (2002). Plague pneumonia. Curr Infect Dis Rep 4, 244–248.[CrossRef][Medline]
Guyton, A. C. (1947). Measurement of the respiratory volumes of laboratory animals. Am J Physiol 150, 70–77.
Heath, D. G., Anderson, G. W., Jr, Mauro, J. M., Welkos, S. L., Andrews, G. P., Adamovicz, J. & Friedlander, A. M. (1998). Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16, 1131–1137.[CrossRef][Medline]
Hill, J., Eyles, J. E., Elvin, S. J., Healey, G. D., Lukaszewski, R. A. & Titball, R. W. (2006). Administration of antibody to the lung protects mice against pneumonic plague. Infect Immun 74, 3068–3070.
Inglesby, T. V., Dennis, D. T., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Friedlander, A. M., Hauer, J. & other authors (2000). Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 283, 2281–2290.
Jones, T., Adamovicz, J. J., Cyr, S. L., Bolt, C. R., Bellerose, N., Pitt, L. M., Lowell, G. H. & Burt, D. S. (2006). Intranasal protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine 24, 1625–1632.[CrossRef][Medline]
Krishna, G. & Chitkara, R. K. (2003). Pneumonic plague. Semin Respir Infect 18, 159–167.[Medline]
Lathem, W. W., Crosby, S. D., Miller, V. L. & Goldman, W. E. (2005). Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity. Proc Natl Acad Sci U S A 102, 17786–17791.
Lathem, W. W., Price, P. A., Miller, V. L. & Goldman, W. E. (2007). A plasminogen-activating protease specifically controls the development of primary pneumonic plague. Science 315, 509–513.
Perry, R. D. & Fetherston, J. D. (1997). Yersinia pestis – etiologic agent of plague. Clin Microbiol Rev 10, 35–66.[Abstract]
Peterson, J. W., Comer, J. E., Baze, W. B., Noffsinger, D. M., Wenglikowski, A., Walberg, K. G., Hardcastle, J., Pawlik, J., Bush, K. & other authors (2007). Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect Immun 75, 3414–3424.
Riedel, S. (2005). Plague: from natural disease to bioterrorism. Proc (Bayl Univ Med Cent) 18, 116–124.[Medline]
Roy, C. J. & Pitt, M. L. M. (2005). Infectious Disease Aerobiology: Aerosol Challenge Methods. Boca Raton, FL: CRC Press.
Sha, J., Agar, S. L., Baze, W. B., Olano, J. P., Fadl, A. A., Erova, T. E., Wang, S., Foltz, S. M., Suarez, G. & other authors (2008). Braun lipoprotein (Lpp) contributes to the virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague. Infect Immun 76, 1390–1409.
Smith, P. N. (1959). Pneumonic plague in mice: gross and histopathology in untreated and passively immunized animals. J Infect Dis 104, 78–84.[Medline]
Smith, P. N., McCamish, J., Seely, J. & Cooke, G. M. (1957). The development of pneumonic plague in mice and the effect of paralysis of respiratory cilia upon the course of infection. J Infect Dis 100, 215–222.[Medline]
Williamson, E. D., Stagg, A. J., Eley, S. M., Taylor, R., Green, M., Jones, S. M. & Titball, R. W. (2007). Kinetics of the immune response to the (F1 + V) vaccine in models of bubonic and pneumonic plague. Vaccine 25, 1142[CrossRef][Medline]
Received 4 February 2008;
revised 5 March 2008;
accepted 26 March 2008.
This article has been cited by other articles:
![]() |
R. J. Thomas, D. Webber, A. Collinge, A. J. Stagg, S. C. Bailey, A. Nunez, A. Gates, P. N. Jayasekera, R. R. Taylor, S. Eley, et al. Different Pathologies but Equal Levels of Responsiveness to the Recombinant F1 and V Antigen Vaccine and Ciprofloxacin in a Murine Model of Plague Caused by Small- and Large-Particle Aerosols Infect. Immun., April 1, 2009; 77(4): 1315 - 1323. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |